Literature DB >> 2906248

Vasodilating effect of the new beta-blocker tilisolol hydrochloride in humans.

T Imaizumi1, A Takeshita, N Nakamura, Y Hirooka, S Suzuki, M Yoshida, M Nakamura.   

Abstract

The effects of a new beta-blocker, (+/-)-4-(3-tert-butylamino-2-hydroxypropoxy)-2-methyl-1(2H)-isoquinolino ne hydrochloride (tilisolol hydrochloride, N-696), on forearm circulation were examined and compared with those of propranolol in healthy young males. N-696 (30 mg/d for 7 days) decreased heart rate from 75 +/- 4 to 56 +/- 2 bpm (p less than 0.01) and decreased mean blood pressure from 86 +/- 2 to 79 +/- 2 mmHg (p less than 0.05) (n = 7). Propranolol (60 mg/d for 7 days) decreased heart rate from 62 +/- 1 to 51 +/- 2 (p less than 0.01) and decreased mean blood pressure from 83 +/- 3 to 73 +/- 3 mmHg (p less than 0.01) (n = 7). Resting forearm blood flow and forearm vascular resistance were not altered by N-696, whereas propranolol decreased forearm blood flow (p less than 0.05) and increased forearm vascular resistance (p less than 0.01). Reflex forearm vasoconstriction was examined by measuring forearm vascular resistance with a strain gauge plethysmograph during lower body negative pressure (LBNP). The regression line relating central venous pressure and forearm vascular resistance during LBNP was shifted toward the resistance axis by propranolol but was not altered by N-696. Propranolol augmented forearm vascular responses to intraarterially infused norepinephrine but N-696 did not alter them. Thus, in contrast to propranolol, N-696 lowered blood pressure and heart rate without peripheral vasoconstriction and did not augment forearm vasoconstrictive responses to norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906248

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs.

Authors:  Q Liu; I Nakae; M Takahashi; A Takaoka; M Kinoshita
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 2.  Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.